Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation. (6th May 2022)
- Record Type:
- Journal Article
- Title:
- Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation. (6th May 2022)
- Main Title:
- Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation
- Authors:
- Arabyarmohammadi, Sara
Leo, Patrick
Viswanathan, Vidya Sankar
Janowczyk, Andrew
Corredor, German
Fu, Pingfu
Meyerson, Howard
Metheny, Leland
Madabhushi, Anant - Abstract:
- Abstract : PURPOSE: Allogenic hematopoietic stem-cell transplant (HCT) is a curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Relapse post-HCT is the most common cause of treatment failure and is associated with a poor prognosis. Pathologist-based visual assessment of aspirate images and the manual myeloblast counting have shown to be predictive of relapse post-HCT. However, this approach is time-intensive and subjective. The premise of this study was to explore whether computer-extracted morphology and texture features from myeloblasts' chromatin patterns could help predict relapse and prognosticate relapse-free survival (RFS) after HCT. MATERIALS AND METHODS: In this study, Wright-Giemsa–stained post-HCT aspirate images were collected from 92 patients with AML/MDS who were randomly assigned into a training set ( S t = 52) and a validation set ( S v = 40). First, a deep learning–based model was developed to segment myeloblasts. A total of 214 texture and shape descriptors were then extracted from the segmented myeloblasts on aspirate slide images. A risk score on the basis of texture features of myeloblast chromatin patterns was generated by using the least absolute shrinkage and selection operator with a Cox regression model. RESULTS: The risk score was associated with RFS in S t (hazard ratio = 2.38; 95% CI, 1.4 to 3.95; P = .0008) and S v (hazard ratio = 1.57; 95% CI, 1.01 to 2.45; P = .044). We also demonstrate that this resultingAbstract : PURPOSE: Allogenic hematopoietic stem-cell transplant (HCT) is a curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Relapse post-HCT is the most common cause of treatment failure and is associated with a poor prognosis. Pathologist-based visual assessment of aspirate images and the manual myeloblast counting have shown to be predictive of relapse post-HCT. However, this approach is time-intensive and subjective. The premise of this study was to explore whether computer-extracted morphology and texture features from myeloblasts' chromatin patterns could help predict relapse and prognosticate relapse-free survival (RFS) after HCT. MATERIALS AND METHODS: In this study, Wright-Giemsa–stained post-HCT aspirate images were collected from 92 patients with AML/MDS who were randomly assigned into a training set ( S t = 52) and a validation set ( S v = 40). First, a deep learning–based model was developed to segment myeloblasts. A total of 214 texture and shape descriptors were then extracted from the segmented myeloblasts on aspirate slide images. A risk score on the basis of texture features of myeloblast chromatin patterns was generated by using the least absolute shrinkage and selection operator with a Cox regression model. RESULTS: The risk score was associated with RFS in S t (hazard ratio = 2.38; 95% CI, 1.4 to 3.95; P = .0008) and S v (hazard ratio = 1.57; 95% CI, 1.01 to 2.45; P = .044). We also demonstrate that this resulting signature was predictive of AML relapse with an area under the receiver operating characteristic curve of 0.71 within S v . All the relevant code is available at GitHub. CONCLUSION: The texture features extracted from chromatin patterns of myeloblasts can predict post-HCT relapse and prognosticate RFS of patients with AML/MDS. Abstract : … (more)
- Is Part Of:
- JCO Clinical Cancer Informatics. Volume 6(2022)
- Journal:
- JCO Clinical Cancer Informatics
- Issue:
- Volume 6(2022)
- Issue Display:
- Volume 6, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 6
- Issue:
- 2022
- Issue Sort Value:
- 2022-0006-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-05-06
- Subjects:
- 616.994
- Journal URLs:
- http://journals.lww.com/pages/default.aspx ↗
- DOI:
- 10.1200/CCI.21.00156 ↗
- Languages:
- English
- ISSNs:
- 2473-4276
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21667.xml